About David Cleevely
David Cleevely is the founder of Analysys, and Managing Director of Analysys Group. His focus areas include authority on the digital economy, regularly commenting on industry trends and prospects at international conferences and in the media. He has also worked with governments at a national and supra-national level to create the policy frameworks which encourage innovation and growth. He advised the UK government on its firstname.lastname@example.org report, and, also contributed to government thinking on convergence and the Internet. David backed the development of the Cambridge Network, which promotes the high-tech activities of the Cambridge region, primarily via an Analysys-designed Web site. He is also Chairman of Abcam (the world's first totally Internet-based antibody company) and VBN, an Analysys spin-off which provides hosted Web sites for organisations wishing to develop online communities.
Latest David Cleevely News
Sep 28, 2021
Sanome , a London, UK-based health startup, raised £2m in first round of funding. The round was led by Heal Capital, with participation from Crista Galli Ventures, Selvedge Ventures, o2h Ventures, Meltwind and a number of high-profile angels including David Cleevely and Pam Garside. The investment will be used to expand the team across London, Amsterdam, and Cambridge; deliver on key strategic and commercial partnerships to develop and validate the first set of IVD candidates. Founded by experienced entrepreneurs Benedikt von Thüngen (CEO) and Dr Marc van der Schee (Chief Medical Officer), Sanome has developed a diagnostics innovation engine that combines biomarkers to develop medical grade, at home diagnostic products (IVDs) effectively. The company’s home test are clinically validated to improve patient outcomes and reduce healthcare costs. FinSMEs 28/09/2021
David Cleevely Investments
David Cleevely has made 5 investments. Their latest investment was in Sanome as part of their Seed VC on September 9, 2021.
David Cleevely Investments Activity
Series B - II